Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Viva Biotech Holdings specializes in drug discovery and development services, leveraging its proprietary platform to enhance the efficiency of the drug development process. The company operates primarily in China, with a growing presence in global markets, providing services to pharmaceutical companies and biotech firms.
Viva Biotech generates revenue primarily through contract research services, which involve providing drug discovery and development support to pharmaceutical companies. The company benefits from strong pricing power due to its proprietary technologies and established relationships with clients, allowing it to command premium pricing.
New client contracts in drug discovery services
Regulatory approvals for drugs developed in collaboration with partners
Expansion into international markets, particularly in Europe and North America
Technological advancements in drug discovery platforms
Regulatory changes that could impact drug approval processes
Technological disruption from new drug discovery methodologies
Increased competition from other biotech firms offering similar services
Potential for larger pharmaceutical companies to internalize drug discovery processes
Moderate liquidity risk due to reliance on cash flow from operations
Potential for increased operational costs if client contracts are not renewed
moderate - The biotechnology sector is somewhat insulated from economic downturns, but funding for R&D can be sensitive to broader economic conditions.
Higher interest rates can increase the cost of capital for biotech firms, potentially impacting their ability to fund R&D and affecting valuations in the sector.
minimal - The company has a low debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors looking for exposure to the biotech sector's potential for high returns from innovative drug development.
high - The stock has shown significant volatility, particularly in response to market sentiment and regulatory news.